Skip Navigation



Annals of Oncology Advance Access published online on September 12, 2005
Annals of Oncology, doi:10.1093/annonc/mdi369
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/11/1817    most recent
mdi369v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hotta, K.
Right arrow Articles by Tanimoto, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hotta, K.
Right arrow Articles by Tanimoto, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology
Received March 16, 2005
Revised July 4, 2005
Accepted July 14, 2005

Original article

Continued gefitinib treatment after disease stabilisation prolongs survival of Japanese patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience

K. Hotta 1*, K. Matsuo 2, H. Ueoka 1, K. Kiura 1, M. Tabata 1, S. Harita 3, K. Gemba 4, T. Yonei 5, A. Bessho 6, and M. Tanimoto 1

1 Department of Medicine II, Okayama University Medical School, Okayama, Japan
2 Division of Epidemiology and Prevention, Aichi Centre Research Institute, Nagoya, Japan
3 Department of Medicine, Chugoku Central Hospital, Fukuyama, Japan
4 Department of Respiratory Medicine, Okayama Rousai Hospital, Okayama, Japan
5 Department of Respiratory Medicine, National Hospital Organisation Okayama Medical Centre, Okayama, Japan
6 Department of Medicine, National Hospital Organisation Shikoku Cancer Centre, Matsuyama, Japan

* To whom correspondence should be addressed.
K. Hotta, E-mail: khotta{at}md.okayama-u.ac.jp


  Abstract

Background: This study aimed to investigate the survival outcome of patients with non-small-cell lung cancer (NSCLC) who had obtained disease stabilisation with gefitinib treatment and to clarify the effect of continued treatment with gefitinib on prognosis.

Patients and methods: We reviewed the clinical records of 365 Japanese patients with NSCLC who received gefitinib (250 mg/day).

Results: Of 324 (89%) patients assessable for response, 147 (45%) obtained disease stabilisation and 71 (22%) patients achieved an objective response. Overall survival in patients obtaining disease stabilisation was significantly longer than in patients with progressive disease (median survival time 12.1 versus 4.4 months; P <0.0001). In patients obtaining disease stabilisation, those who continued gefitinib treatment until disease progression tended to have longer overall and progression-free survival compared with those discontinuing gefitinib treatment (1-year survival rate 52.1% versus 36.6%, P = 0.08; 1-year progression-free survival rate 31.8% versus 5.2%, P = 0.001). Multivariate analysis showed discontinuing gefitinib was an independent risk factor for progression-free survival (hazard ratio 1.66; 95% confidence interval 1.07-2.56; P = 0.022) but not for overall survival.

Conclusions: Our findings indicate the importance of achieving disease stabilisation with gefitinib treatment and continued gefitinib treatment in Japanese patients with disease stabilisation, although further studies are required to confirm these findings.

Keywords: disease stabilisation; gefitinib; non-small-cell lung cancer; survival.

K. Hotta and K. Matsuo contributed equally to this work.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
K. Hotta, K. Kiura, Y. Fujiwara, N. Takigawa, I. Oze, N. Ochi, M. Tabata, and M. Tanimoto
Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer
Ann. Onc., May 1, 2009; 20(5): 829 - 834.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.